[1] Ansel, H.C., Popovich, N.G. and Allen, L.V. (2005) Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. 8th Edition, Lippincott Williams & Willkins.
[2] Zade, P.S., Kabitkwar, P.S. and Sakarkar, D.M. (2009) Formulation, Evaluation and Optimization of Fast Dissolving Tablet Containing Tizanidine Hydrochloride. International Journal of Pharm Tech Research, 1, 34-42.
[3] Sharma, D. (2013) Formulation Development and Evaluation of Fast Disintegrating Tablets of Salbutamol Sulphate for Respiratory Disorders. ISRN Pharmaceutics, 2013, 1-13. http://dx.doi.org/10.1155/2013/674507
[4] Chandrasekhar, R., Hassan, Z., Alhusban, F., Smith, A.M. and Mohammed, A.R. (2009) The Role of Formulation Excipients in The Development of Lyophilized Fast-Disintegrating Tablets. European Journal of Pharmaceutics and Biopharmaceutics, 72, 119-129. http://dx.doi.org/10.1016/j.ejpb.2008.11.011
[5] Amin, A.F. (2006) Emerging Trends in the Development of Orally Disintegrating Tablet Technology.
[6] Okuda, Y., Irisawa, Y., Okimoto, K., Osawa, T. and Yamashita, S. (2009) A New Formulation for Orally Disintegrating Tablets Using a Suspension Spray-Coating Method. International Journal of Pharmaceutics, 382, 80-87.
http://dx.doi.org/10.1016/j.ijpharm.2009.08.010
[7] Bhowmik, D., Chiranjib, B., Krishnakant, P. and Chandira, R.M. (2009) Fast Dissolving Tablet: An Overview. Journal of Chemical and Pharmaceutical Research, 1, 163-177.
[8] Salustio, P.J., Feio, G., Figuirinhas, J.L., Pinto, J.F. and Cabral Marques, H.M. (2008) The Influence of the Preparation Methods on the Inclusion of Model Drugs in β-Cyclodextrin Cavity. European Journal of Pharmaceutics and Biopharmaceutics, 71, 377-386. http://dx.doi.org/10.1016/j.ejpb.2008.09.027
[9] Sachan, R., Khatri, K. and Kasture, S.B. (2010) Self-Emulsifying Drug Delivery System a Novel Approach for Enhancement of Bioavalibility. International Journal of PharmTech Research, 2, 1738-1745.
[10] Savjani, K.T., Gajjar, A.K. and Savjani, J.K. (2012) Drug Solubility: Importance and Enhancement Techniques. ISRN Pharmaceutics, 2012, 195727.
[11] Ishiguro, T., Morishita, E., Iohara, D., Hirayama, F., Wada, K., Motoyama, K., Arima, H. and Uekama, K. (2011) Some Pharmaceutical and Inclusion Properties of 2-Hydroxybutyl-&Beta-cyclodextrin Derivative. International Journal of Pharmaceutics, 419, 161-169. http://dx.doi.org/10.1016/j.ijpharm.2011.07.044
[12] Osborne, R.J., Slevin, M.L., Hunter, R.W. and Hamer, J. (1985) Cardiotoxicity of Intravenous Domperidone. Lancet, 386, 385. http://dx.doi.org/10.1016/S0140-6736(85)92515-2
[13] Challa, R., Ahuja, A., Ali, J. and Khar, R.K. (2005) Cyclodextrins in Drug Delivery: An Updated Review. AAPS PharmSciTech, 6, 329-357. http://dx.doi.org/10.1208/pt060243
[14] Goel, H., Vora, N. and Rana, V. (2008) A Novel Approach to Optimize and Formulate Fast Disintegrating Tablets for Nausea and Vomiting. American Association of Pharmaceutical Scientists, 9, 774-781.
[15] Shimpi, S., Chauhan, B. and Shimi, P. (2005) Cyclodextrins: Application in Different Routes of Drug Administration. Acta Pharmaceutica, 55, 139-156.
[16] (1996) ASEAN Guidelines for Validation of Analytical Procedures. ICH Q2B.
[17] Nalluri, B.N., Chowdary, K.P., Murthy, K.V., Hayman, A.R. and Becket, G. (2003) Physicochemical Characterization and Dissolution Properties of Nimesulide-Cyclodextrin Binary Systems. AAPS PharmSciTech, 4, 6-17.
http://dx.doi.org/10.1208/pt040102
[18] (2007) British Pharmacopoeia, II.
[19] Costa, P. and Lobo, J.M.S. (2001) Modeling and Comparison of Dissolution Profiles. European Journal of Pharmaceutical Sciences, 13, 123-133. http://dx.doi.org/10.1016/S0928-0987(01)00095-1